

# Recessive *REEP1* mutation is associated with congenital axonal neuropathy and diaphragmatic palsy

OPEN 

Gudrun Schottmann,  
MD  
Dominik Seelow, PhD  
Franziska Seifert  
Susanne Morales-  
Gonzalez  
Esther Gill  
Katja von Au, MD  
Arpad von Moers, MD  
Werner Stenzel, MD  
Markus Schuelke, MD

Correspondence to  
Dr. Schuelke:  
markus.schuelke@charite.de

## ABSTRACT

**Objective:** To identify the underlying genetic cause of a congenital neuropathy in a 5-year-old boy as part of a cohort of 32 patients from 23 families with genetically unresolved neuropathies.

**Methods:** We used autozygosity mapping coupled with next-generation sequencing to investigate a consanguineous family from Lebanon with 1 affected and 2 healthy children. Variants were investigated for segregation in the family by Sanger sequencing. A splice site mutation was further evaluated on the messenger RNA level by quantitative reverse transcription PCR. Subsequently, a larger cohort was specifically screened for receptor expression-enhancing protein 1 (*REEP1*) gene mutations.

**Results:** We detected a homozygous splice donor mutation in *REEP1* (c.303+1-7GTAATAT>AC, p.F62Kfs23\*; NM\_022912) that cosegregated with the phenotype in the family, leading to complete skipping of exon 4 and a premature stop codon. The phenotype of the patient is similar to spinal muscular atrophy with respiratory distress type 1 (SMARD1) with additional distal arthrogryposis and involvement of the upper motor neuron manifested by pronounced hyperreflexia.

**Conclusion:** To date, only dominant *REEP1* mutations have been reported to be associated with a slowly progressive hereditary spastic paraplegia. The findings from our patient expand the phenotypical spectrum and the mode of inheritance of *REEP1*-associated disorders. Recessive mutations in *REEP1* should be considered in the molecular genetic workup of patients with a neuromuscular disorder resembling SMARD1, especially if additional signs of upper motor neuron involvement and distal arthrogryposis are present. *Neurol Genet* 2015;1:e32; doi: 10.1212/NXG.000000000000032

## GLOSSARY

**BSCL2** = Berardinelli-Seip congenital lipodystrophy type 2 gene; **ER** = endoplasmic reticulum; **ExAC** = Exome Aggregation Consortium; **HSP** = hereditary spastic paraplegia; **mRNA** = messenger RNA; **REEP1** = receptor expression-enhancing protein 1 gene; **SMARD1** = spinal muscular atrophy with respiratory distress type 1; **WES** = whole-exome sequencing.

Dominant mutations in the gene encoding the receptor expression-enhancing protein 1 (*REEP1*) are associated with hereditary spastic paraplegia (HSP), designated SPG31.<sup>1</sup> *REEP1* is associated with the mitochondria<sup>1</sup> and the endoplasmic reticulum (ER) and protects neurons from the accumulation of neurotoxic aggregates.<sup>2</sup> *REEP1* mutations account for approximately 3%–10% of autosomal dominant HSPs; *REEP1* is the third most frequent causative gene (following *SPAST* [spastin] and *ATL1* [atlastin 1]).<sup>3,4</sup> More than 40 *REEP1* mutations have been reported to date, comprising mainly small frameshift mutations that are all transmitted in autosomal dominant fashion.<sup>1,3–6</sup> Patients with dominant *REEP1* mutations have a slowly progressive “pure” HSP that is only rarely accompanied by peripheral neuropathy.<sup>3–5</sup> Only a single family has been described with isolated distal motor neuropathy.<sup>7</sup> We report a patient with a recessive *REEP1* mutation with

Supplemental data  
at [Neurology.org/ng](http://Neurology.org/ng)

From the Departments of Neuropediatrics (G.S., D.S., F.S., S.M.-G., E.G., M.S.) and Neuropediatrics/SPZ (K.v.A.), NeuroCure Clinical Research Center, Charité-Universitätsmedizin, Berlin, Germany; the Department of Neuropathology (W.S.), Charité-Universitätsmedizin Berlin, Germany; and the DRK Children’s Hospital Berlin (A.v.M.), Germany.

Funding information and disclosures are provided at the end of the article. Go to [Neurology.org/ng](http://Neurology.org/ng) for full disclosure forms. The Article Processing Charge was paid by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

a much more severe phenotype involving severe congenital axonal neuropathy, hyperreflexia, respiratory distress, and distal arthrogryposis, making the clinical phenotype similar to that of patients with spinal muscular atrophy with respiratory distress type 1 (SMARD1).

**METHODS Standard protocol approvals, registrations, and patient consents.** The study was approved by the institutional review board of the Charité (EA1/222/08). Parents provided written informed consent for all aspects of the study according to the Declaration of Helsinki.

**Mutation detection.** We performed initial autozygosity mapping followed by whole-exome sequencing (WES) of a consanguineous family with 1 affected patient (figure 1) and 2 healthy siblings. For autozygosity mapping, we investigated the index patient (patient II:03, figure 2A) and 2 healthy siblings (II:01 and II:02) using the Affymetrix 6.0 GeneChip SNP array and performed subsequent analysis using HomozygosityMapper2012 software (<http://www.homozygositymapper.org>) to identify genomic regions that were homozygous solely in the index patient.<sup>8</sup> Subsequent WES was performed on the index patient after capture with the SureSelect V4 kit (Agilent Technologies, Santa Clara, CA) and sequencing on a HiSeq 2000 machine (Illumina, San Diego, CA), yielding 82 Mio  $2 \times 101$  bp paired-end reads that were aligned to the human GRCh37.p11 (hg19/Ensembl 72) genomic sequence. The mean coverage was  $\times 112$ , and 87.9% of the captured sequences were covered more than  $\times 10$ . After fine adjustment, the raw alignments were called for deviations from the reference in all coding exons  $\pm 20$  bp flanking regions. Each of these variants was submitted to MutationTaster2 software<sup>9</sup> to search for potentially pathogenic variants. These variants were further filtered for a recessive inheritance model (the variant allele occurs in homozygous state in  $>20$  healthy individuals from the ExAC database release 0.3 [Exome Aggregation Consortium; Cambridge, MA; <http://exac.broadinstitute.org>] or  $>10$  healthy persons in the 1000 Genomes Project) and a dominant inheritance model (the allele was present in  $>20$  individuals in the 1000 Genomes Project or  $>100$  individuals from ExAC). Segregation of the mutation with the phenotype in the family was verified by PCR and Sanger sequencing using the BigDye protocol (Life Technologies, Carlsbad, CA) on an ABI 3500 genetic analyzer using following the oligonucleotides: forward: 5'-TCC TTC AAA AGG GCA GTG TT-3'; reverse: 5'-CAC CAC TAT TTC TAA ACA CGT CTC A-3'. Fragment length was analyzed with forward: 5'-TGC TGT CTC CCT ACA CAA AAG-3' and reverse: FAM-GAA AGA ATG AAA GAC ATG-3' oligonucleotides.

**Reverse transcription PCR on the complementary DNA level.** Index patient and 2 control fibroblast lines were grown to confluency and trypsinized, and total RNA was isolated using the RNeasy Kit (Qiagen, Venlo, the Netherlands) reagent. A further RNA sample was isolated from a muscle biopsy specimen of the patient. Total RNA was reversely transcribed with SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, CA) and random hexamers. Oligonucleotide complementary DNA primers flanking exon 4 (forward: 5'-CCT GCG TAT TAT TCC TAC AAG GC-3'; reverse: 5'-CTT GGA AGC AGC CAT CAC AG-3') were used for PCR, and the resulting products were separated by agarose electrophoresis and subjected to bidirectional automatic Sanger sequencing.


**Histology.** Processing and staining of muscle cryostat and of transmission electron microscopic samples were performed as described previously.<sup>10,11</sup>

**RESULTS Case report.** The now 5-year-old boy was born at term after a normal pregnancy to healthy first-cousin parents from Lebanon. Two older brothers are healthy. At birth, the patient presented with an equinovarus foot deformity, contractures of the distal phalanges, and a high-arched palate (figure 1, A–C). Later, progressive distally pronounced weakness and hypotonia, mainly of the lower extremities, became evident. Neurography of the sensory portion of the median nerve revealed axonal neuropathy with reduced amplitudes of 2.9  $\mu$ V (normal  $12.0 \pm 5.9 \mu$ V) but normal nerve conduction velocity of 43.1 m/s (normal  $> 39.7$  m/s). We were unable to elicit any measurable motor response or F-waves after stimulation of the median, peroneal, and tibial nerves. EMG could not be performed because of compliance problems. In contrast, muscle tendon reflexes were very brisk with enlarged trigger zones (albeit without upgoing plantar reflexes), indicating upper motor neuron involvement (video 1 at [Neurology.org/ng](http://Neurology.org/ng)). Mutation analysis of *PMP22*, *MPZ*, *GDAP1*, *EGR2*, *SH3TC2*, *IGHMBP2*, and *TRPV4* genes had yielded normal results. Cranial MRI at 6 months was normal. Muscle histology showed fiber type grouping but no relevant atrophy (figure 1F). Electron microscopy of the axons and endplates (figure 1, G and H) demonstrated loss of presynaptic neurofilaments and a condensed axoplasm with degeneration of organelles in the “bouton terminal.” Respiratory distress and paradoxical breathing due to diaphragmatic palsy were diagnosed at 11 months (figure 1D, video 2). Following recurrent severe respiratory tract infections with acute respiratory failure, noninvasive nocturnal mask ventilation was initiated at 13 months of age. In recent years, the muscle weakness has not progressed; however, he still cannot sit without support. On the other hand, mental and speech development is apparently normal.

The healthy parents received a thorough clinical neurologic investigation and displayed normal muscle tone, strength, and reflexes as well as normal sensation, fine motor skills, and gait pattern. The only subtle abnormalities were a high palate and a mild increase in the foot arch of the father. Neurography of motor (median, tibial, peroneal) and sensory (median, sural) nerves in both parents showed normal results.

**Identification of a *REEP1* mutation.** Autozygosity mapping revealed several regions on chromosomes 1, 2, 10, 11, and 13 (=27.3 Mbp), comprising 132 protein-coding genes. WES revealed 3 homozygous variants within the autozygous regions that were predicted to be potentially disease causing by MutationTaster2 software. Two of them could be excluded (table e-1).

**Figure 1** Clinical images of the patient




(A) Talipes equinovarus foot deformity. (B) Arthrogryposis of the hand, with inability to extend the fingers. (C) High-arched palate as a sign of intrauterine muscle weakness. (D) Diaphragmatic palsy with eventration (white arrowheads). (E) Hematoxylin and eosin staining of the quadriceps muscle rules out grouped fiber atrophy. (F) Staining with anti-myosin heavy chain (fast) antibodies reveals fiber type grouping as a sign of denervation/reinnervation. Type II fibers are depicted in brown. (G) Electron microscopy of the neuromuscular endplate reveals condensation of the axoplasm and degeneration of axonal organelles (open arrowhead), including mitochondria and loss of presynaptic neurofilaments, while the subneural clefts appear normal. Five of 5 endplates that could be discovered in the muscle biopsy specimen had identical abnormalities. (H) Normal neuromuscular endplate of the quadriceps muscle of an age-matched control at the same magnification for comparison.

The remaining homozygous splice site mutation in *REEPI* at the donor splice site of exon 4 (c.303+1-7GTAATAT>AC, p.F62Kfs23\*; NM\_022912) was predicted to abrogate the splice site, resulting in a frameshift and premature termination codon after 23

nonoriginal amino acids. This variant was not listed in the ExAC database or the 1,000 Genomes Project as a known polymorphism. Homozygosity of the mutation was confirmed by Sanger sequencing and cosegregated with the phenotype in the family (figure 2C). The

**Figure 2** Molecular genetic findings in the patient



(A) Pedigree of the consanguineous family. (B) Autozygosity mapping of the family. The red bars depict the candidate regions that comprise 132 protein-coding genes. The genetic coordinates refer to the genome build GRCh37.p11 (hg19/Ensembl 72). (C) GeneScan analysis of the insertion/deletion mutation at the intron 4 splice donor site, with homozygosity for the mutation in the patient and heterozygosity in all other family members. (D) Sequence trace of the mutation on genomic DNA. (E) Investigation of receptor expression-enhancing protein 1 (*REEP1*) on the complementary DNA from cultured fibroblasts verifies skipping of the 121 bp exon 4. No normally spliced transcript was detected in the patient; the mutant bands are faint, possibly because of nonsense-mediated messenger decay. Co = control; mut = mutant band; NTC = nontemplate control; wt = wild-type band.

splicing defect was verified on the level of the messenger RNA (mRNA) from fibroblasts and muscle (figure 2E). No full-length mRNA transcript was detected in the patient. Repeated Western blots (anti-REEP1, SIGMA

SAB2101976, 1:50–1:500) failed to show the presence of the REEP1 protein in extracts from fibroblasts and muscle of the patient and of normal controls, possibly because of low expression levels in these tissues.

Finally, we performed molecular genetic testing of *REEP1* by sequencing all exons in 3 patients from a cohort of patients with a genetically unresolved SMARD1-like phenotype featuring clinical signs of additional involvement of the upper motor neuron. However, we did not detect any further mutation.

**DISCUSSION** The known heterozygous dominant mutations in *REEP1* are associated with a slowly progressive form of HSP and are only rarely associated with a neuropathy. Only one family with isolated motor axonal neuropathy without any signs of spasticity has been described. Based on functional studies, the authors suspected that heterozygous loss-of-function mutations may result in upper motor neuron pathology, while mutations with a presumed toxic gain of function might cause lower motor neuron disease.<sup>7</sup> The >40 published dominant mutations of *REEP1* are evenly distributed over the entire reading frame, and neither clear genotype-phenotype correlation nor mutational hot spot has been established (figure e-1); recessive mutations have not been reported. Hence the location of the mutation in our family cannot be linked to a special phenotype. Of note, a previously reported mutation (c.303G>A) of the same exon 4 splice donor was associated with a pure HSP phenotype.<sup>3</sup> In a *Reep1*-deficient mouse model, animals developed a severe gait disorder resembling human HSP that was much more pronounced in homozygous animals than in heterozygous animals.<sup>12</sup>

In our patient, the functional relevance of the splice site mutation could be demonstrated on the mRNA level in fibroblasts and muscle tissue but not on the protein level, presumably because *REEP1* expression levels are too low in these tissues to be detectable by Western blot.<sup>1,13</sup> It is interesting that the heterozygous parents are healthy despite their obvious haploinsufficiency. These findings may hint at additional factors in the genetic background of the parents with an influence on *REEP1*-related pathogenicity, although this remains speculative without having investigated further families with a similar phenotype.

A similar constellation was reported for another disease associated with the dominant p.Asn88Ser Berardinelli-Seip congenital lipodystrophy type 2 gene (*BSCL2*) mutation, which had been detected in different unrelated families. This mutation is associated with a broad spectrum of neuromuscular disease phenotypes, ranging from motor neuropathy to complex HSP, but was also seen in asymptomatic heterozygous carriers.<sup>14</sup> Of note, homozygous *BSCL2* mutations are known to be associated with an entirely different disorder, congenital generalized lipodystrophy type 2.<sup>15</sup>

Similar to the *BSCL2* protein, *REEP1* is localized at the ER and is relevant for ER shaping.<sup>16</sup> Recently, it was shown in a *Drosophila* model that overexpression of *reep1* prevents tau-mediated neurodegeneration and promotes neuronal resistance to ER stress.<sup>2</sup> Thus, *REEP1*-associated disorders may also be summarized as ER stress diseases, displaying different phenotypes depending on the type of disturbed ER function. However, the precise underlying mechanisms remain to be elucidated.

To date, only a few genes are known to be associated with a SMARD-like phenotype. Both *IGHMBP2* (*SMARD1*) and *LASIL* (*SMARD2* with X-chromosomal inheritance) play a role in RNA processing, protein translation,<sup>17</sup> and ribosomal biogenesis.<sup>18</sup> In this respect, a function at the ER might hint at a pathogenetic link between *IGHMBP2* and *REEP1*; however, this requires further experimental evidence. In addition, mutations in the riboflavin transporters *SLC25A2* and *SLC25A3* may also mimic *SMARD1*, just like mutations in *MEGF10*, a gene involved in the regulation of satellite cells.<sup>19</sup> This reflects the clinical and functional heterogeneity of SMARD-like phenotypes.

Our study expands the known phenotypical spectrum of *REEP1*-associated neuromuscular disorders and highlights that recessive *REEP1* mutations should be considered in the genetic workup of patients with a *SMARD1*-like phenotype, especially if presenting with signs of upper motor neuron involvement.

## AUTHOR CONTRIBUTIONS

Guðrun Schottmann: recruited, investigated, and phenotyped the patients; performed neurophysiologic investigations; validated the results of the WES; wrote the first draft of the manuscript. Dominik Seelow: developed and applied bioinformatic tools for genetic variant analysis. Franziska Seifert: performed RT-PCR. Susanne Morales-Gonzalez: performed Western blotting. Esther Gill: performed and analyzed the Sanger sequencing. Katja von Au: phenotyped the patient. Arpad von Moers: phenotyped the patient. Werner Stenzel: performed neuropathologic investigations in the muscle tissue. Markus Schuelke: investigated and phenotyped the patients; performed the autozygosity mapping and haplotype analysis; validated the results of the WES; supervised the work and obtained funding support; wrote the first draft of the manuscript.

## STUDY FUNDING

The project was funded by the Deutsche Forschungsgemeinschaft (SFB 665 TP C4) to M.S. and the NeuroCure Center of Excellence (Exc 257) to M.S.

## DISCLOSURE

Guðrun Schottmann, Dominik Seelow, Franziska Seifert, Susanne Morales-Gonzalez, Esther Gill, Katja von Au, and Arpad von Moers report no disclosures. Werner Stenzel has served on the editorial boards of *Neuromuscular Disorders* and *Neuropathology and Applied Neurobiology*. Markus Schuelke has served on the editorial board of *Biomedical Research International*. Go to [Neurology.org/ng](http://Neurology.org/ng) for full disclosure forms.

Received July 11, 2015. Accepted in final form September 8, 2015.

## REFERENCES

1. Züchner S, Wang G, Tran-Viet KN, et al. Mutations in the novel mitochondrial protein *REEP1* cause hereditary

- spastic paraplegia type 31. *Am J Hum Genet* 2006;79:365–369.
2. Appocher C, Klima R, Feiguin F. Functional screening in *Drosophila* reveals the conserved role of REEP1 in promoting stress resistance and preventing the formation of Tau aggregates. *Hum Mol Genet* 2014;23:6762–6772.
  3. Beetz C, Schüle R, Deconinck T, et al. REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. *Brain* 2008;131:1078–1086.
  4. Goizet C, Depienne C, Benard G, et al. REEP1 mutations in SPG31: frequency, mutational spectrum, and potential association with mitochondrial morpho-functional dysfunction. *Hum Mutat* 2011;32:1118–1127.
  5. Hewamadduma C, McDermott C, Kirby J, et al. New pedigrees and novel mutation expand the phenotype of REEP1-associated hereditary spastic paraplegia (HSP). *Neurogenetics* 2009;10:105–110.
  6. Schlang KJ, Arming L, Epplen JT, Stemmler S. Autosomal dominant hereditary spastic paraplegia: novel mutations in the REEP1 gene (SPG31). *BMC Med Genet* 2008;9:71.
  7. Beetz C, Pieber TR, Hertel N, et al. Exome sequencing identifies a REEP1 mutation involved in distal hereditary motor neuropathy type V. *Am J Hum Genet* 2012;91:139–145.
  8. Seelow D, Schuelke M. HomozygosityMapper2012—bridging the gap between homozygosity mapping and deep sequencing. *Nucleic Acids Res* 2012;40:W516–W520.
  9. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods* 2014;11:361–362.
  10. von Renesse A, Petkova MV, Lützkendorf S, et al. POMK mutation in a family with congenital muscular dystrophy with merosin deficiency, hypomyelination, mild hearing deficit and intellectual disability. *J Med Genet* 2014;51:275–282.
  11. Schuelke M, Cervós-Navarro J. Degenerative changes in unmyelinated nerve fibers in late-infantile neuronal ceroidlipofuscinosis. A morphometric study of conjunctival biopsy specimens. *Acta Neuropathol* 1998;95:175–183.
  12. Beetz C, Koch N, Khundadze M, et al. A spastic paraplegia mouse model reveals REEP1-dependent ER shaping. *J Clin Invest* 2013;123:4273–4282.
  13. Hurt CM, Björk S, Ho VK, Gilsbach R, Hein L, Angelotti T. REEP1 and REEP2 proteins are preferentially expressed in neuronal and neuronal-like exocytotic tissues. *Brain Res* 2014;1545:12–22.
  14. Auer-Grumbach M, Schlotter-Weigel B, Lochmüller H, et al. Phenotypes of the N88S Berardinelli-Seip congenital lipodystrophy 2 mutation. *Ann Neurol* 2005;57:415–424.
  15. Magré J, Delépine M, Khallouf E, et al; BSCL Working Group. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. *Nat Genet* 2001;28:365–370.
  16. Park SH, Zhu PP, Parker RL, Blackstone C. Hereditary spastic paraplegia proteins REEP1, spastin, and atlastin-1 coordinate microtubule interactions with the tubular ER network. *J Clin Invest* 2010;120:1097–1110.
  17. Guenther U-P, Handoko L, Lagerbauer B, et al. IGHMBP2 is a ribosome-associated helicase inactive in the neuromuscular disorder distal SMA type 1 (DSMA1). *Hum Mol Genet* 2009;18:1288–1300.
  18. Butterfield RJ, Stevenson TJ, Xing L, et al. Congenital lethal motor neuron disease with a novel defect in ribosome biogenesis. *Neurology* 2014;82:1322–1330.
  19. Logan CV, Lucke B, Pottinger C, et al. Mutations in MEGF10, a regulator of satellite cell myogenesis, cause early onset myopathy, areflexia, respiratory distress and dysphagia (EMARDD). *Nat Genet* 2011;43:1189–1192.

# Neurology<sup>®</sup> Genetics

**Recessive *REEP1* mutation is associated with congenital axonal neuropathy and diaphragmatic palsy**

Gudrun Schottmann, Dominik Seelow, Franziska Seifert, et al.

*Neurol Genet* 2015;1;

DOI 10.1212/NXG.0000000000000032

**This information is current as of October 22, 2015**

*Neurol Genet* is an official journal of the American Academy of Neurology. Published since April 2015, it is an open-access, online-only, continuous publication journal. Copyright © 2015 American Academy of Neurology. All rights reserved. Online ISSN: 2376-7839.



<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://ng.neurology.org/content/1/4/e32.full.html">http://ng.neurology.org/content/1/4/e32.full.html</a>
<b>Supplementary Material</b>	Supplementary material can be found at: <a href="http://ng.neurology.org/content/suppl/2015/10/22/1.4.e32.DC1">http://ng.neurology.org/content/suppl/2015/10/22/1.4.e32.DC1</a> <a href="http://ng.neurology.org/content/suppl/2015/10/23/1.4.e32.DC2">http://ng.neurology.org/content/suppl/2015/10/23/1.4.e32.DC2</a>
<b>References</b>	This article cites 19 articles, 1 of which you can access for free at: <a href="http://ng.neurology.org/content/1/4/e32.full.html##ref-list-1">http://ng.neurology.org/content/1/4/e32.full.html##ref-list-1</a>
<b>Citations</b>	This article has been cited by 2 HighWire-hosted articles: <a href="http://ng.neurology.org/content/1/4/e32.full.html##otherarticles">http://ng.neurology.org/content/1/4/e32.full.html##otherarticles</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>All clinical neurophysiology</b> <a href="http://ng.neurology.org/cgi/collection/all_clinical_neurophysiology">http://ng.neurology.org/cgi/collection/all_clinical_neurophysiology</a> <b>All Genetics</b> <a href="http://ng.neurology.org/cgi/collection/all_genetics">http://ng.neurology.org/cgi/collection/all_genetics</a> <b>Genetic linkage</b> <a href="http://ng.neurology.org/cgi/collection/genetic_linkage">http://ng.neurology.org/cgi/collection/genetic_linkage</a> <b>Muscle disease</b> <a href="http://ng.neurology.org/cgi/collection/muscle_disease">http://ng.neurology.org/cgi/collection/muscle_disease</a> <b>Peripheral neuropathy</b> <a href="http://ng.neurology.org/cgi/collection/peripheral_neuropathy">http://ng.neurology.org/cgi/collection/peripheral_neuropathy</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://ng.neurology.org/misc/about.xhtml#permissions">http://ng.neurology.org/misc/about.xhtml#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://ng.neurology.org/misc/addir.xhtml#reprintsus">http://ng.neurology.org/misc/addir.xhtml#reprintsus</a>

*Neurol Genet* is an official journal of the American Academy of Neurology. Published since April 2015, it is an open-access, online-only, continuous publication journal. Copyright © 2015 American Academy of Neurology. All rights reserved. Online ISSN: 2376-7839.

